COVID-19 Infection Clinical Trial
Official title:
The Status of Parathyroid Hormone Secretion and Its Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer in Hospitalized Covid-19 Patients
Verified date | December 2020 |
Source | Bezmialem Vakif University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs. This cytokine-mediated widespread inflammation can also affect the parathyroid glands, resulting in impaired parathyroid secretion. Researchers evaluated the levels of parathyroid hormone, calcium, phosphorus, and alkaline phosphatase in patients hospitalized for COVID-19 infection. Researchers excluded patients on intensive care therapy and patients with known parathyroid disease. The researchers examined the association of parathyroid hormone secretion with COVID-19 disease, white blood cells, neutrophil / lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone level of healthy people without COVID-19 infection and known parathyroid disease with the parathyroid hormone level of Covid-19 patients.
Status | Completed |
Enrollment | 150 |
Est. completion date | December 9, 2020 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - To accept research. - Being over the age of 18. - COVID 19 test results to be positive. - Not taking parathyroid disease medication before. - Receiving inpatient treatment in the COVID service in the hospital. Exclusion Criteria: - Not accepting research. - Be under the age of 18. - Negative COVID 19 test results for patients. - COVID patients treated as outpatient. - Parathyroid disease in the healthy control group. |
Country | Name | City | State |
---|---|---|---|
Turkey | Bezmialem VU | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Bezmialem Vakif University | Didem Ertorul |
Turkey,
di Filippo L, Formenti AM, Doga M, Frara S, Rovere-Querini P, Bosi E, Carlucci M, Giustina A. Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. Endocrine. 2020 Nov 9. doi: 10.1007/s12020-020-02541-9. [Epub ahead of print — View Citation
Somasundaram NP, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Dissanayake HA, Yogendranathan N, Gamage KKK, de Silva NL, Sumanatilleke M, Katulanda P, Grossman AB. The Impact of SARS-Cov-2 Virus Infection on the Endocrine System. J Endocr Soc. 2020 Jul 2; — View Citation
Sun JK, Zhang WH, Zou L, Liu Y, Li JJ, Kan XH, Dai L, Shi QK, Yuan ST, Yu WK, Xu HY, Gu W, Qi JW. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY). 2020 Jun 25;12(12):11287-11295. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of parathyroid hormone between groups | In the study, serum parathyroid hormone results of the Covid patient group and non-Covid control groups were recorded and compared statistically. | 90 days | |
Primary | Comparison of calcium between groups | In the study, serum calcium results of the Covid patient group and non-Covid control groups were recorded and compared statistically. | 90 days | |
Primary | Comparison of phosphorus between groups | In the study, serum phosphorus results of the Covid patient group and non-Covid control groups were recorded and compared statistically. | 90 days | |
Primary | Comparison of alkaline phosphatase between groups | In the study, serum alkaline phosphatase results of the Covid patient group and non-Covid control groups were recorded and compared statistically. | 90 days | |
Primary | White blood cells (WBC) results of Covid 19 patient group | In the study, serum WBC results were recorded in Covid 19 patient groups. | 90 days | |
Primary | Neutrophil / lymphocyte ratio (N/LO) results of Covid 19 patient group | In the study, serum N/LO results were recorded in Covid 19 patient groups. | 90 days | |
Primary | C-reactive protein (CRP) results of Covid 19 patient group | In the study, serum CRP results were recorded in Covid 19 patient groups. | 90 days | |
Primary | Fibrinogen results of Covid 19 patient group | In the study, serum fibrinogen results were recorded in Covid 19 patient groups. | 90 days | |
Primary | Procalcitonin results of Covid 19 patient group | In the study, serum procalcitonin results were recorded in Covid 19 patient groups. | 90 days | |
Primary | Ferritin results of Covid 19 patient group | In the study, serum ferritin results were recorded in Covid 19 patient groups. | 90 days | |
Primary | D-dimer results of Covid 19 patient group | In the study, serum D-dimer results were recorded in Covid 19 patient groups. | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04997551 -
Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19
|
Phase 3 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
Terminated |
NCT04455815 -
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Recruiting |
NCT05792878 -
Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
|
||
Completed |
NCT04659200 -
Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
|
||
Recruiting |
NCT04470583 -
Evaluating Clinical Parameters of COVID-19 in Pregnancy
|
||
Withdrawn |
NCT04377568 -
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
|
Phase 2 | |
Completed |
NCT04848610 -
The Factors That Affect the Infection of COVID-19
|
||
Recruiting |
NCT04582903 -
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
|
||
Recruiting |
NCT06032000 -
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
|
Phase 1 | |
Terminated |
NCT04941703 -
"CHANGE COVID-19 Severity"
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04639466 -
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
|
Phase 1/Phase 2 | |
Completed |
NCT04575038 -
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
|
Phase 2 | |
Recruiting |
NCT05022446 -
The Impact of COVID-19 on Pulmonary Procedures
|
||
Completed |
NCT04347798 -
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
|
||
Active, not recruiting |
NCT04650178 -
Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
|
||
Recruiting |
NCT04169542 -
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
|
||
Recruiting |
NCT04382781 -
Immunosupressive Treatment in COVID-19 Patients
|